Equity
€57,221 =
L2Be Pharma paid out €14,987 in dividends. That is 100% of the 2025 profit.
L2Be Pharma
Lifetime
5 annual accounts with figures on one time axispeak €67,586 (2021)
€36,781▲ 13.0%
peak €46,799 (2021)
€14,987▼ 32.1%
peak €100,117 (2023)
€57,221unchanged
€96,349▲ 6.2%
Board1 name since 2021
1 director
Documentsfilings and deeds
23-06-202638 days before the deadline
2025micro format
Gross margin from €32,550 to €36,781Result from €22,063 to €14,987Dividend €14,987
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 26,973 companies had the same profile as L2Be Pharma has now. Each dot stands for 68 companies, two years later.
94.8%
were still trading
3.5%
stopped another way
1.6%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 26,973 companies, not a prediction for L2Be Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0764501936
Registered office moved from Estinne - Rue Provinciale to Binche - Rue Saint-Paul
New registered office: 7130 Binche - Rue Saint-Paul 47 · Previous registered office: 7120 Estinne - Rue Provinciale 47 · General meeting of 01-08-2024 · Gazette deed
Registered office moved from Binche to Estinnes
New registered office: Rue Provinciale 47 à 7120 Estinnes · Previous registered office: Rue Saint-Paul 47 à 7130 Binche · Board meeting of 01-07-2022 · Gazette deed
First establishment
Rue Saint-Paul 47, Binche
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| L2Be Pharma Binche | €153,570 | €36,781 | 37.3% | - |
| Lionel Lambert PEB Oupeye | €163,234 | €42,256 | 92.0% | - |
| ERANOV PHARMA Mouscron | €153,094 | €33,805 | 58.0% | - |
| ENGINEERING CONSULTING GROUP Estaimpuis | €157,048 | €25,388 | 82.7% | - |
| Lean Services Silly | €130,090 | €35,161 | 2.3% | - |
| THE QUALIFIED PERSON Dour | €110,785 | €37,066 | 25.9% | - |
| URBAN TOP Dour | €136,591 | €40,025 | 73.2% | - |
These companies have the same main activity as L2Be Pharma: other professional, scientific and technical activities (NACE 74999). They are comparable in size and age: total assets between €111,000 and €163,000, founded between 2019 and 2022.
Official details
Source: KBO- Status
- Active since 02-03-2021Normal situation
- Activity
- Other professional, scientific and technical activitiesNACE 74999and 3 others
- Establishment unit
- 2.314.045.1637130 Binche, since 12-03-2021
- Financial year end
- 31 December
- Peppol
- Reachable since 20-06-2025
Annual accounts 2025
- €153,570▲ 3.8%
- Filing
- Filed on 23-06-2026, 38 days before the end of the filing period
Insights on L2Be Pharma
L2Be Pharma files the micro format. That format states no turnover. The gross margin fell from €67,586 in 2021 to €36,781 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about L2Be Pharma
- What is the company number of L2Be Pharma?
- The company number of L2Be Pharma is 0764.501.936. The VAT number is the same number with BE in front: BE 0764.501.936.
- Where is L2Be Pharma based?
- The registered office is at Rue Saint-Paul 47, 7130 Binche.Company details
- What does L2Be Pharma do?
- According to the KBO register, the main activity is other professional, scientific and technical activities (NACE 74999).
- What is the legal form of L2Be Pharma?
- L2Be Pharma is a private limited company (BV).
- When was L2Be Pharma founded?
- L2Be Pharma was founded on 02-03-2021.
- Is L2Be Pharma still active?
- Yes, L2Be Pharma is an active enterprise in the KBO register.
- What is the turnover of L2Be Pharma?
- The turnover in financial year 2025 is ≈ €150,000. This figure is estimated from the gross margin of €36,781 and 2,935 comparable companies of the same size. It probably lies between €89,000 and €270,000. It is a rough estimate.Financials
- Is L2Be Pharma profitable?
- In financial year 2025, L2Be Pharma made a profit of €14,987.
- Where can I find the annual accounts of L2Be Pharma?
- L2Be Pharma filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of L2Be Pharma due?
- L2Be Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.